YK11: What Science Knows So Far
TL:DR. YK11 is an anabolic SARM that promotes cell growth. There are many unknowns especially when it comes to side effects as there are no human or animal trials.
The research available on this compound has been led by a guy named Yuichiro Kanno. His papers are on Japanese sites, and while I love the Japanese and the fucked up porn that has brought me so much joy over the years, navigating .jp sites is an enormous challenge for finding abstracts that I think will help.
When I finally did find the data I was looking for, it’s evident that this compound is only partially understood. There are no human trials, and no live animal trials, at least not published… this one is still being tested against cultured cells. There’s also a lack of conclusions being drawn by the researchers. In a compound like LGD4033, there are nice LBM% graphs that are easy to interpret. Not so with YK11, or at least not yet and probably not for another few years. Caveat out of the way let’s focus on what science has established and why this is such a fascinating compound, and go from there.
The researchers own conclusion. Fucking awesome.
I.e. it’s a partial agonist. Partial agonists are interesting since they can be used for prostate cancer and muscle/bone wasting diseases… or muscle building in our case, without impacting the little guys (testicles) downstairs. It is selective to MDA-MB 453 cells, or breast tissue – that’s not necessarily good or bad, #justsaying, though I suppose this is good news in that it’s not cardio selective, or some other bad preference.
YK11 seems to inhibit the activity of DHT… at what level, I can’t say just yet, but that looks promising. I see potential for this to be used alongside androgenic compounds to help counter the hair shedding many users experience.
In a follow up study, mRNA was looked at and I’m so glad they examined this, because there were significant changes in mRNA expression when compared to control or just DHT. I cover mRNA a little here, but essentially it’s what is telling your cells how and where to form. Higher amounts mean that your body is directing growth / repair efficiently. Really promising for age related disease when you also consider that it’s a partial agonist – it helps build muscle efficiently.
And on that topic of building muscle efficiently, YK11 upregulates follistatin, which is an antagonist of myostatin. Myostatin limits muscle growth, so upregulating follistatin should increase muscle mass. The researchers also show that YK11 induces myogenic differentiation, which is fancy wording for it almost certainly causes muscle growth, further making the argument on its anabolic nature.
I’m not clear, and it is yet to be examined (in a lab setting), the kind of lmb% change we might expect from such a compound. I’m optimistic that this will be the next step in the evaluation of this compound. It’s worth noting that all tests to date have been in-vitro, i.e. injected, and the subject cells were on a dish under a microscope. Such practical matters as is if it bio-available, effective dosage and safety have not been evaluated.